소아환자에서 아지스로마이신 처방 분석
Evaluation of Azithromycin Prescriptions for Pediatric Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Azithromycin has broad spectrum and is effective to treat several bacterial respiratory tract infection. It is also relatively safe and tolerable to pediatric patient. Careful use of azithromycin is also required for the prescribers because it could cause cardiovascular toxicity (QTc prolongation) and ototoxicity. There has been no study on duration of azithromycin use in pediatric patients in Korea. Methods: The outpatient sample data on the azithromycin prescription was obtained from Korean health insurance review and assessment service. The characteristics of azithromycin prescription were analyzed with two different years (2011 and 2014). Results: Total 4,215 cases were analyzed. The azithromycin was prescribed the most frequently in the children (73.2% in 2011 and 62.5% in 2014) and for the condition of bronchopneumonia (28.7% in 2011 and 21.7% in 2014) in both years. The duration of prescribed for azithromycin has significantly different between 2011 and 2014. In 2014, 94.3% of prescription were indicated less than 5 days, but 86.6% were in 2011. Acute bronchiolitis and bronchopneumonia prescriptions more longer duration of treatment compared with acute bronchitis and others. Conclusion: The pattern of prescribing azithromycin has been changed for the treatment of several infectious diseases in pediatric patients. The rate of appropriate duration of azithromycin treatment has increased.
Abstract
Background: Azithromycin has broad spectrum and is effective to treat several bacterial respiratory tract infection. It is also relatively safe and tolerable to pediatric patient. Careful use of azithromycin is also required for the prescribers because it could cause cardiovascular toxicity (QTc prolongation) and ototoxicity. There has been no study on duration of azithromycin use in pediatric patients in Korea. Methods: The outpatient sample data on the azithromycin prescription was obtained from Korean health insurance review and assessment service. The characteristics of azithromycin prescription were analyzed with two different years (2011 and 2014). Results: Total 4,215 cases were analyzed. The azithromycin was prescribed the most frequently in the children (73.2% in 2011 and 62.5% in 2014) and for the condition of bronchopneumonia (28.7% in 2011 and 21.7% in 2014) in both years. The duration of prescribed for azithromycin has significantly different between 2011 and 2014. In 2014, 94.3% of prescription were indicated less than 5 days, but 86.6% were in 2011. Acute bronchiolitis and bronchopneumonia prescriptions more longer duration of treatment compared with acute bronchitis and others. Conclusion: The pattern of prescribing azithromycin has been changed for the treatment of several infectious diseases in pediatric patients. The rate of appropriate duration of azithromycin treatment has increased.
참고문헌 (22)
- Drew RH, "Azithromycin-spectrum of activity, pharmacokinetics, and clinical Applications", Pharmacotherapy, 12, pp.161~173 (1992)
- Bahal N, "The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin", Ann Pharmacother, 26, pp.46~55 (1992)
- "Drug information"[URL]
- Chow AW, "IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults", Clin Infect Dis, 54, pp.e72~e112 (2012)
- Bradley JS, "The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America", Clin Infect Dis, 53, pp.e25~e76 (2011)
- Pickering LK, "Red Book: 2012 Report of the Committee on Infectious Diseases" (2012), American Academy of Pediatrics
- Ray WA, "Azithromycin and the risk of cardiovascular death", N Engl J Med, 366, pp.1881~1890 (2012)
- Bizjak ED, "Intravenous azithromycininduced ototoxicity", Pharmacotherapy, 19, pp.245~248 (1999)
- Eric M, "Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia", JAMA, 311, pp.2199~2208 (2014)
- Mortensen EM, "Efficacy and safety of longterm antibiotics (macrolides) for the treatment of chronic rhinosinusitis", Curr Allergy Asthma Rep, 14, pp.416~422 (2014)
- Svanström H, "Use of azithromycin and death from cardiovascular causes", N Engl J Med, 368, pp.1704~1712 (2013)
- "Drug information for pediatric patients"[URL]
- Kogan R, "Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children", Pediatr Pulmonol, 35, pp.91~98 (2003)
- Arguedas A, "Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin", clavulanate for the treatment of children with acute otitis media, 2011, pp.15, 240~248
- Patel C, "1-2 Grams of azithromycin and cardiovascular death among commercially insured persons aged 15-44 years", Sex Transm Dis, 41, pp.S130~ (2014)
- Lloyd M, "Exploring attitudes and opinions of pharmacists toward delivering prescribing error feedback:A qualitative case study using focus group interviews", Res Social Adm Pharm, 12, pp.461~474 (2016)
- Sethuraman U, "Prescription errors before and after introduction of electronic medication alert system in a pediatric emergency department", Acad Emerg Med, 22, pp.714~719 (2015)
- Kabbara WK, "Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia", Ther Clin Risk Manag, 22, pp.639~647 (2015)
- Murphy JL, "Adverse events in pediatric patients receiving long-term oral and intravenous antibiotics", Hosp Pediatr, 6, pp.330~338 (2016)
- Aljfout Q, "Antibiotics for post-tonsillectomy morbidity: comparative analysis of a single institutional experience", J Clin Med Res, 8, pp.385~388 (2016)
- "Medication labeling information"[URL]